[1]. Koltai, T.; Fliegel, L. The Relationship between Trop-2, Chemotherapeutic Drugs, andChemoresistance. Int. J. Mol. Sci. 2024, 25, 87. https://doi.org/10.3390/ijms25010087
[2]. Vasan, N.; Baselga, J.; Hyman, D.M. A view on drug resistance in cancer. Nature 2019, 575, 299–309.
[3]. Burchenal, J.H.; Holmberg, E.A. The utility of resistant leukemias in screening forchemotherapeutic activity. Ann. N. Y. Acad. Sci. 1958, 76, 826–837.
[4]. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The differentmechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull. 2017, 7, 339.
[5]. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: Anevolving paradigm. Nat. Rev. Cancer 2013, 13, 714–726.
[6]. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drugresistance in cancer: An overview. Cancers 2014, 6, 1769–1792.
[7]. Wang, J.Q.; Yang, Y.; Cai, C.Y.; Teng, Q.X.; Cui, Q.; Lin, J.; Assaraf, Y.G.; Chen, Z.S. Multidrugresistance proteins (MRPs): Structure, function and the overcoming of cancer multidrugresistance. Drug Resist. Updates 2021, 54, 100743.
[8]. Catalano, A.; Iacopetta, D.; Ceramella, J.; Scumaci, D.; Giuzio, F.; Saturnino, C.; Aquaro, S.;Rosano, C.; Sinicropi, M.S. Multidrug resistance (MDR): A widespread phenomenon inpharmacological therapies. Molecules 2022, 27, 616.
[9]. Calabrese, G.; Crescenzi, C.; Morizio, E.; Palka, G.; Guerra, E.; Alberti, S. Assignment of TACSTD1(alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2(alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet.Genome Res. 2001, 92, 164–165.
[10]. Guan, H.; Guo, Z.; Liang, W.; Li, H.; Wei, G.; Xu, L.; Xiao, H.; Li, Y. Trop2 enhances invasion ofthyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer 2017, 17, 486.
[11]. Wu, B.; Yu, C.; Zhou, B.; Huang, T.; Gao, L.; Liu, T.; Yang, X. Overexpression of TROP2 promotesproliferation and invasion of ovarian cancer cells. Exp. Ther. Med. 2017, 14, 1947–1952.
[12]. Shastry, M.; Jacob, S.; Rugo, H.S.; Hamilton, E. Antibody-drug conjugates targeting TROP-2:Clinical development in metastatic breast cancer. Breast 2022, 66, 169–177.
[13]. Bignotti, E.; Todeschini, P.; Calza, S.; Falchetti, M.; Ravanini, M.; Tassi, R.A.; Ravaggi, A.; Bandiera,E.; Romani, C.; Zanotti, L.; et al. Trop-2 overexpression as an independent marker for pooroverall survival in ovarian carcinoma patients. Eur. J. Cancer 2010, 46, 944–953.
[14]. Guan, G.F.; Zhang, D.J.; Wen, L.J.; Yu, D.J.; Zhao, Y.; Zhu, L.; Guo, Y.Y.; Zheng, Y. Prognostic value
of TROP2 in human nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol. 2015, 8, 10995.
[15]. Guerra, E.; Trerotola, M.; Aloisi, A.L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli,M.; Alberti, S. The Trop-2 signalling network in cancer growth. Oncogene 2013, 32, 1594–1600.
[16]. Sun, X.; Jia, L.; Wang, T.; Zhang, Y.; Zhao, W.; Wang, X.; Chen, H. Trop2 binding IGF2R inducesgefitinib resistance in NSCLC by remodeling the tumor microenvironment. J. Cancer 2021, 12,5310.
[17]. Varughese, J.; Cocco, E.; Bellone, S.; Bellone, M.; Todeschini, P.; Carrara, L.; Schwartz, P.E.;Rutherford, T.J.; Pecorelli, S.; Santin, A.D. High-grade, chemotherapy-resistant primary ovariancarcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and arehighly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.Gynecol. Oncol. 2011, 122, 171–177.
[18]. Sin, S.T.; Li, Y.; Liu, M.; Ma, S.; Guan, X.Y. TROP-2 exhibits tumor suppressive functions incervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol. Oncol. 2019, 152,185–193.
[19]. Frederick, B.A.; Helfrich, B.A.; Coldren, C.D.; Zheng, D.; Chan, D.; Bunn, P.A., Jr.; Raben, D.Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and necksquamous cell carcinoma and non–small cell lung carcinoma. Mol. Cancer Ther. 2007, 6, 1683–1691.
[20]. Yamashita, T.; Mori, Y.; Alzaaqi, S.M.; Yashiro, M.; Sawada, T.; Hirakawa, K.; Nakada, H. Inductionof Trop-2 expression through the binding of galectin-3 to MUC1. Biochem. Biophys. Res.Commun. 2019, 516, 44–49.
[21]. Pathi S., Li X., Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and inducesdegradation of specificity protein (Sp) transcription factors. Mol. Carcinog. 2014;53((Suppl.1)):E53–E61
